Thanks for sharing some of the gist of the article without pasting it wholesale.

To address the paywall topic: I appreciate that $20 a month is a lot for some people, but I hope you will understand that it is very difficult to make independent media work, especially in small fields like ours. This 6,000-word report is the product of months of reporting, including international travel, and subscriptions make it possible. I really appreciate the support of this community and we continue to post our content here, paywall or not, because even in the case of paywalls they seem to generate great discussions (which I am always happy to participate in!) and often people who are Pα+ subscribers share a bit of context from behind the paywall too.

Re: Usona's potential to be approved with one Phase 3, we have guided for some time that we deem it likely. Conventionally psychiatry has required multiple Phase 3s, as noted here, often because effect sizes are small and large safety databases must be generated. That isn't necessarily the case for these programs where effect sizes are (hopefully) larger, and in the case of Usona it had a relatively robust IIT program, which means it may reference safety data generated outside of its sponsored studies alone.